WO1998009601A2 - Process to prepare pharmaceutical compounds - Google Patents

Process to prepare pharmaceutical compounds Download PDF

Info

Publication number
WO1998009601A2
WO1998009601A2 PCT/US1997/015668 US9715668W WO9809601A2 WO 1998009601 A2 WO1998009601 A2 WO 1998009601A2 US 9715668 W US9715668 W US 9715668W WO 9809601 A2 WO9809601 A2 WO 9809601A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
hydrogen
phenyl
substituted
Prior art date
Application number
PCT/US1997/015668
Other languages
French (fr)
Other versions
WO1998009601A3 (en
Inventor
Andrew H. Fray
Michael J. Martinelli
Eric D. Moher
Original Assignee
Eli Lilly And Company
University Of Hawaii
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, University Of Hawaii, Wayne State University filed Critical Eli Lilly And Company
Priority to AU43343/97A priority Critical patent/AU4334397A/en
Priority to EP97941436A priority patent/EP0934250A4/en
Priority to IL12864397A priority patent/IL128643A0/en
Priority to CA002264527A priority patent/CA2264527A1/en
Priority to JP10512938A priority patent/JP2001500128A/en
Priority to BR9711695-5A priority patent/BR9711695A/en
Publication of WO1998009601A2 publication Critical patent/WO1998009601A2/en
Publication of WO1998009601A3 publication Critical patent/WO1998009601A3/en
Priority to IL128643A priority patent/IL128643A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Definitions

  • This invention relates to the fields of pharmaceutical and organic chemistry and provides a process for preparing cryptophycin compounds useful as anti- microtubule agents.
  • Cryptophycin compounds can be useful for the treatment of cancer and neoplasms, and are thus useful pharmaceutical agents.
  • the literature discloses a protocol for cyclizing certain cryptophycin compounds.
  • This three-step sequence (hereinafter "Barrow synthetic sequence") commenced with the conversion of trichloroethyl ester to the corresponding carboxylic acid using zinc and acetic acid. Conversion of crude to the amino carboxylate was accomplished with trifluoroacetic acid followed by an aqueous basic work-up.
  • the presently claimed process provides a shorter (two-steps) process which is more adaptable for large scale or commercial preparation of the macrocyclic core of cryptophycin derivatives.
  • the claimed process can reduce reagent expense, as well as minimize the potential waste-stream issues associated with the use of certain reagents in the Barrow synthetic sequence. Further, purification via the claimed process may be accomplished without chromatography, which is expensive and difficult to implement on a large scale.
  • the presently claimed invention provides a process for preparing a compound of Formula II
  • Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, d-Ci? alkyl, C?-C ⁇ 2 alkenyl, C 6 -C 1? alkynyl, NR 51 R 52 , COR 5 , OR 5 ', and Formula Ar'
  • R >5 3 1 1 is selected from the group consisting of hydrogen and C- C 3 alkyl
  • R 5 is selected from the group consisting of hydrogen and d ⁇ C 3 alkyl
  • R 53 is selected from the group consisting of C ⁇ C ⁇ 2 alkyl
  • R 54 is selected from the group consisting of hydrogen, d ⁇ C 6 alkyl, Ci-dalkyl (R 5 ' R 57" R 57'” ) , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( tert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR 57 , P0 3 H, S0 3 H, S0 2 R 5 ⁇ , N(R 59 )R 60 , NHCHR 61 ', CN, NO?, halogen, OR 62 , CH 2 (0)R 6 ", -
  • R 95 is selected from the group consisting of -R 98 NH 3 ;
  • R 9b and R 96' are each independently selected from the group consisting of hydrogen and d-C 6 alkyl, -R 97 NH 3 , and -R 99 NR 99' R 99" ;
  • R 97 is selected from the group consisting of C ⁇ -C fe alkyl;
  • R 98 is selected from the group consisting of d-Ce alkyl;
  • R 99 is d-C 6 alkyl;
  • R 99' and R 9C " ' are each independently selected from the group consisting of hydrogen and C ⁇ -C 6 alkyl;
  • R 100 is selected from the group consisting of hydrogen, and s i ( R 1 0 , R 1 02 R 10 3 ) .
  • R 101 is C ⁇ -C 6 alkyl
  • R o? i s d-Ce, alkyl ;
  • R 103 is C -C 6 al kyl
  • R 104 is selected from the group consisting of C ( 0) d -C 6 alkylN (R 10fa ) (R 59 ) R 60 , C ( 0) d-C 6 alkylN + , fused bicyclic, and
  • R 105 is selected from the group consisting of C(0,d-C 6 alkyl,
  • R 106 is selected from the group consisting of hydrogen, -d alkyl, C(0)OR 107 ;
  • R 107 is selected from the group consisting of hydrogen, d _ d alkyl, CR 108 R 109 R no
  • R 108 is selected from the group consisting of hydrogen and C ⁇ -C 6 alkyl
  • R 109 is selected from the group consisting of hydrogen and
  • R 110 is selected from the group consisting of hydrogen and d-C 6 alkyl
  • R 55 is selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, C (R 57' R 57" R 57'” ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR 57 , P0 3 H, S0 3 H, S0 2 R 58 ,
  • R 5b i s selected from the group consisting of hydrogen, C ⁇ -C b al kyl , C ( R 7 ' R 57 " R 57" ' ) , simple unsubstituted aromat ic, simple substituted aromatic , phenyl , COOR f57 , P0 3 H, S0 3 H, S0 2 R 58 ,
  • R ⁇ is selected from the group cons i sting o f hydrogen and d -
  • R 57' is selected from the group consisting of hydrogen, halogen, and C1-C12 alkyl
  • R 57" is selected from the group consisting of hydrogen, halogen, and C ⁇ C ⁇ 2 alkyl
  • R 57'" is selected from the group consisting of hydrogen, halogen, and d-C 12 alkyl
  • R 58 is selected from the group consisting of hydrogen and Cj- C 1? alkyl
  • R 59 is selected from the group consisting of hydrogen, (C ⁇
  • C fc alkyl, tert-butoxycarbonyl, carbo-tert-butoxy (t-BOC) and fluorenylmethoxycarbonyl (FMOC) ;
  • R 60 is selected from the group consisting of hydrogen and (Ci-d) alkyl
  • R 61 is selected from the group consisting of hydrogen, OR 1 ' 4 ,
  • R 61' is selected from the group consisting of hydrogen, OR 64 ,
  • R 6? is selected from hydrogen, and d-C b alkyl
  • R 62' is selected from hydrogen, OH, OR 62 , and d ⁇ C b alkyl
  • R bi is selected from hydrogen and Cj-d, alkyl
  • R 64 is selected from the group consisting of hydrogen, (Ci-
  • R G5 is selected from the group consisting of hydrogen and Ci-
  • R 65' is selected from the group consisting of hydrogen and
  • R 66 is selected from the group consisting of hydrogen and Ci- d alkyl and fluorenylmethoxycarbonyl (FMOC) ;
  • R 6 ' is selected from the group consisting of hydrogen and Ci-
  • R 3 is a lower alkyl group
  • R 4 is H or OH
  • R 5 is H or OH
  • R 4 and R 5 may be taken together to form a second bond between 3 and d
  • R 6 is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring (d-C 6 ) alkyl, (d-C 8 ) cycloalkyl, substituted C 3 -C 8 cycloalkyl, substituted (C,-C b ) alkyl, a group of the formula III'
  • R 7 is selected from the group consisting of NR R ',? , R 53 NR R 5? , OR 53 , H and a lower alkyl group;
  • R 51 and R " ' 2 are independently selected from the group consisting of d _ d alkyl;
  • R 53 is d ⁇ C 3 alkyl;
  • R 8 is H or a lower alkyl group; or
  • R 7 and R 8 can form a cyclopropyl ring;
  • R 9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-C 3 -d cycloalkyl, and benzyl;
  • R 10 is H or a lower alkyl group;
  • R n is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl;
  • R ⁇ r ', R l , and R 1 ' are each independently selected from the group consisting of hydrogen, OR 18 , halo, NR 18' R 19' , N0 2 ,
  • R 18 is selected from the group consisting of hydrogen, aryl,
  • R 18' is selected from the group consisting of hydrogen, (d-
  • R 19 is Ci- alkyl, C(0)R 9n" and fluorenylmethoxycarbonyl
  • R 19' is selected from the group consisting of hydrogen, (d ⁇ C alkyl, and C (0) R 90'" ;
  • R 90 , R 90' , R 90" , and R 90" ' are each independently selected from the group consisting of hydrogen, (Ci-d) alkyl, OR 91' and aryl;
  • R 91' is selected from the group consisting of (Ci-d) alkyl, aryl, and hydrogen;
  • R 23 is selected from the group consisting of hydrogen and
  • R 30 is hydrogen or Ci- alkyl
  • R 3 ⁇ may be taken together with the N at C-11 to form a three to seven me bered cyclic ring
  • R 50 is hydrogen or n is 0, 1, or 2; m is 0, 1, or 2; -1-
  • p 0, l,or 2;
  • X is selected from the group consisting of 0, C, S, NH and alkylamino
  • Y is selected from the group consisting of C, O, NH, S, SO,
  • Z is selected fromt he group consisting of -(CH 2 ) n -, -(CH ? ) P -
  • ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; comprising contacting a compound of Formula III
  • M is selected from the group consisting of hydrogen, Na, Li, K, and Cs;
  • X cat is selected from the group consisting of 0, N, and S;
  • y cat _ s selected from the group consisting of 0, N, and S;
  • Rca tl i s selected from the group consisting of C ⁇ C 6 alkyl and aryl
  • R cat2 is selected from the group consisting of C ⁇
  • Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, C] -C ⁇ 2 al kyl , C 2 -C J 2 alkenyl, C 2 -C 12 alkynyl, NRbl l rR-,52 COR s OR 53 and Formula Ar'
  • R 51 is selected from the group consisting of hydrogen and Ci- C 3 alkyl
  • R 52 is selected from the group consisting of hydrogen and d ⁇
  • R 53 is selected from the group consisting of C ⁇ -C ⁇ 2 alkyl
  • R is selected from the group consisting of hydrogen, Ci- alkyl, d ⁇ dalkyl (R 5 ' R b7" R 57'" ) , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( tert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR 57 , PO ⁇ H, S0 3 H, S0 7 R 5 ⁇ , N(R 59 )R 60 , NHOR 61 , NHCHR 61' , CN, N0 2 , halogen, OR 62 , CH 2 (0)R ⁇ ?'
  • R is selected from the group consisting of -R NH 3 ;
  • R 96 and R 96' are each independently selected from the group consisting of hydrogen and Ci- alkyl, -R 9 NH 3 , and -R 9 NR 99'
  • R 97 is selected from the group consisting of C ⁇ -C h alkyl
  • R 98 is selected from the group consisting of C]-C f , alkyl; R 99 is Ci-Ce alkyl;
  • R 99' and R 99" are each independently selected from the group consisting of hydrogen and d _ alkyl;
  • R 100 is selected from the group consisting of hydrogen
  • R 101 is d-Ce alkyl
  • R 102 is d-d alkyl
  • R 103 is d-d alkyl
  • R 104 is selected from the group consisting of C(0)C ⁇ -C b alkylN(R 106 ) (R 59 )R B0 , C (0) C,-C 6 alkylN + , fused bicyclic, and NHR 105 N(R 106 ) (R f,9 )R 60 ;
  • R 105 is selected from the group consisting of C(0)d-C 6 alkyl
  • R 106 is selected from the group consisting of hydrogen, C ⁇ C 6 alkyl, C(0)OR 107 ; R 107 is selected from the group consisting of hydrogen, C ⁇ C alkyl, CR 108 R 109 R 110
  • R 108 is selected from the group consisting of hydrogen and
  • R 109 is selected from the group consisting of hydrogen and d-d alkyl
  • R o is selected from the group consisting of hydrogen and
  • Ci-d alkyl is selected from the group consisting of hydrogen, d-C b alkyl, and C(0)0R 107
  • R 55 is selected from the group consisting of hydrogen, d ⁇ d alkyl, C (R 57' R 57" R 5 ' "' ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR 57 , P0 3 H, S0 3 H, S0 2 R 58 ,
  • R 56 is selected from the group consisting of hydrogen, C ⁇ d alkyl, C (R 7' R ' " R h7'" ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR 57 , P0H, S0 3 H, S0 ? R 58 , NR b9 R 60 , NHOR 61 , NHCHR 61' , (C,-C 6 ) alkylNR b9 R G0 , CN, NO , halogen,
  • R 57 is selected from the group consisting of hydrogen and d- d? alkyl
  • R 57' is selected from the group consisting of hydrogen, halogen, and d-C 12 alkyl
  • R 57" is selected from the group consisting of hydrogen, halogen, and C ⁇ -C 12 alkyl
  • R 57'" is selected from the group consisting of hydrogen, halogen, and C ⁇ -C ⁇ 2 alkyl;
  • R 58 is selected from the group consisting of hydrogen and d-
  • R 59 is selected from the group consisting of hydrogen, (Ci-
  • R 60 is selected from the group consisting of hydrogen and (d-d) alkyl;
  • R 61 is selected from the group consisting of hydrogen, OR ,
  • R 61' is selected from the group consisting of hydrogen, OR 64 , CH 2 NHR 65 , NHR 65' and fluorenylmethoxycarbonyl (FMOC) ;
  • R 62 is selected from hydrogen, and C _ alkyl
  • R 62' is selected from hydrogen, OH, OR 62 , and Ci-d alkyl
  • R 63 is selected from hydrogen and Ci- alkyl
  • R b4 is selected from the group consisting of hydrogen, (Ci-
  • R 65 is selected from the group consisting of hydrogen and d-
  • R 65' is selected from the group consisting of hydrogen and
  • R 66 is selected from the group consisting of hydrogen and d-
  • R 67 is selected from the group consisting of hydrogen and d- C b alkyl
  • R J is a lower alkyl group
  • R 4 is H or OH
  • R ' is H or OH
  • R 4 and R 5 may be taken together to form a second bond between C 13 and d 4 ;
  • R 6 is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring
  • R 7 is selected from the group consisting of NR 51 R 5? , R 53 NR 51 R 51 ,
  • R 51 and R 52 are independently selected from the group consisting of C 1 -C3 alkyl;
  • R 53 is Ci- C 3 alkyl;
  • R 8 is H or a lower alkyl group
  • R 7 and R e can form a cyclopropyl ring
  • R 9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-C 3 -C b cycloalkyl, and benzyl;
  • R 10 is H or a lower alkyl group
  • R 11 is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl;
  • R lb , R 16 , and R 17 are each independently selected from the group consisting of hydrogen, OR 18 , halo, NR 18' R 19' , N0 2 ,
  • R 18 is selected from the group consisting of hydrogen, aryl, d-C 6 alkyl, C(0)R 90 and fluorenylmethoxycarbonyl (FMOC);
  • R 18' is selected from the group consisting of hydrogen, (Ci-
  • R 19 is d-Ce alkyl, C(0)R 90" and fluorenylmethoxycarbonyl ( MOC) ;
  • R :9' is selected from the group consisting of hydrogen, (Ci-
  • R 90 , R 90' , R 90" , and R 90'" are each independently selected from the group consisting of hydrogen, (Ci-Ce) alkyl, OR 91' and aryl; R 91 ' is selected from the group consisting of (C ⁇ -d) alkyl, aryl, and hydrogen;
  • R 2J is selected from the group consisting of hydrogen and
  • R 30 is hydrogen or C ⁇ C 6 alkyl
  • R 30 may be taken together with the N at C-11 to form a three to seven membered cyclic ring; o
  • R 50 is hydrogen or ; n is 0 , 1 , or 2 ; m is 0 , 1 , or 2 ; p is 0 , l , or 2 ;
  • X is selected from the group consisting of 0, C, S, NH and alkylamino
  • Y is selected from the group consisting of C, 0, NH, S, SO, S0 2 and alkylamino;
  • Z is selected fromt he group consisting of -(CH 2 ) n -, - (CH?) P - 0-(CH 2 ) m - and (C 3 -C 5 ) cycloalkyl;
  • ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof.
  • the term "simple alkyl” shall refer to C 2. -C 7 alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain. Examples include, but are in no way limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, propenyl, ethenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, methylated pentyl groups and the like.
  • alkenyl refers to an alkyl group, as defined above, having from one to three double bonds.
  • alkynyl refers to an alkyl group, as defined above, having at least one triple bond. It is especially preferred that alkynyl has only one triple bond.
  • the Ci-Cn 1 alkyl can be straight or branched chain.
  • B-ring Ci-C ⁇ alkyl refers to saturated, unsaturated, branched and straight chain alkyl wherein the B-ring Ci-C ⁇ alkyl group may include up to three (3) non-carbon substituents.
  • non-carbon substituents are most preferredly selected from the group) consisting of OH, SCH phenyl, NH 2 , CO, CONH 2 , C0 2 H, P0 3 H 2 ,
  • R 21 is selected from hydrogen and C 3. -C 3 alkyl
  • (Ci-C ⁇ ) alkyl linker refers to Ci-C ⁇ alkyl group having from zero to three substituents selected from the group consisting of C ⁇ -C6 alkyl, NH 2 and amino acid.
  • amino acid means an organic acid containing an amino group.
  • the term includes both naturally occuring and synthetic amino acids, therefore, the amino group can be, but is not required to be, attached to the carbon next to the acid.
  • the term shall refer to, but is in no way limited to (CH ) 2 NH 2 COOH, (CH 2 ) 3 NH 2 COOC(CH 3 ) 3 , CH 2 NH 2 COOC (CH 3 ) 3 , CH 2 CH (NH 2 ) CH 2 COOH, CH 2 CH(NH 2 )CH 2 COOC(CH 3 )3, and the like.
  • the term “carbohydrate” refers to a class of substituents made up of carbon, hydrogen, and oxygen wherein hydrogen and oxygen are in the same proportions as in water or nearly the proportions as water.
  • the term “carbohydrate” further refers to an aldehyde or ketone alcohol or a compound which on hydrolysis produces and aldehyde or ketone.
  • the term “carbohydrate” is as commonly understood by the skilled artisan. For example, the term refers to, but is in no way limited to, C ⁇ 2 H 2 0n and C 6 H 10 O 5 .
  • amino sugar refers to a carbohydrate group containing from one to three amino substituents at any available position on the carbohydrate molecule .
  • saccharide refers to carbohydrate subunits to form disaccharides or polysaccharides .
  • the term means for example, but in no way limited to, lactose, maltose, sucrose, fructose, starch, and the like.
  • substituted phenyl shall refer to a phenyl group with from one to three non- hydrocarbon substituents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I.
  • substituted benzyl shall refer to a benzyl group with from one to three non- hydrocarbon substitutents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I wherein such substituents may be attached at any available carbon atom.
  • B-ring heterocyclic group refers to aromatic or unsaturated rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur. Especially preferred B-ring heterocyclic groups are selected from, but not limited to, the group consisting of
  • R 20 is selec ed from hydroge alkyl. wherein R 20 is selected from hydrogen and Ci-C ⁇ alkyl.
  • B-ring heteroaromatic group refers to a substituent selected from the group consisting of:
  • cycloalkyl refers to a saturated C-C cycloalkyl group wherein such group may include from zero to three substituents selected from the group consisting of C 1 -C 3 alkyl, halo, and OR 22 wherein R 22 is selected from hydrogen and C 1 -C 3 alkyl. Such substituents may be attached at any available carbon atom. It is especially preferred that cycloalkyl refers to substituted or unsubstituted cyclohexyl.
  • Lower alkoxyl group means any alkyl group of one to five carbon atoms bonded to an oxygen atom.
  • lower alkyl group means an alkyl group of one to five carbons and includes linear and non- linear hydrocarbon chains, including for example, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups.
  • allylically substituted alkene means any alkene having from one to seven carbon atoms which contains an alkyl substitution on it.
  • unsaturated lower alkyl means a lower alkyl group as defined supra , wherein from one to two double bonds are present in the unsaturated lower alkyl substituent.
  • lower alkyl-C 3 ⁇ C 5 cycloalkyl refers to C-C alkyl substituted with a C 3 -C 5 cycloalkyl group.
  • a preferred lower alkyl-C 3 ⁇ C 5 cycloalkyl group is -CH 2 -cyclopropyl; wherein the group is attached to the cryptophycin core structure at R 9 via the CH 2 .
  • epoxide ring means a three- membered ring whose backbone consists of two carbons and an oxygen atom.
  • aziridine ring means a three-me bered ring whose backbone consists of two carbon atoms and a nitrogen atom.
  • sulfide ring means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom.
  • episulfide ring means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom.
  • sulfate group means a five membered ring consisting of a carbon- carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom.
  • cyclopropyl ring means a three member ring whose backbone consists of three carbon atoms.
  • monoalkylphosphate ring means a five membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
  • “simple unsubstituted group” refers to common aromatic rings having 4n+2 ⁇ electrons in a monocyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example but not limited to mdolyl or naphthyl.
  • “simple substituted aromatic group” refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group.
  • fused bicyclic refers to two joined ring systems which are optionally independently saturated, unsaturated, or aromatic. Such groups include but are in no way limited to naphthyl, groups which fuse an unsaturated ring with an aromatic ring, groups having a heterocyclic group fused with a heteroaromatic group, and a heterocyclic group fused with an aromatic group.
  • the fused bicyclic is optionally substituted with one or more substituents selected from the group consisting of Ci- alkyl and halogen.
  • heteroaromatic group refers to aromatic rings which contain one or more non-carbon atoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. It is most preferred that the heteroaromatic group will have from three to eight members in the ring. It is especially preferred that the number of non-carbon members will be from one to three.
  • heterocyclic refers to saturated or unsaturated rings containing one or more non carbon atoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. It is most preferred that the heterocyclic group will have from three to eight members m the ring. It is especially preferred that the number of non-carbon members will be from one to three.
  • halogen or “halo” refers to those members of the group on the periodic table historically known as halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan. Especially preferred halogens are chloro, bromo, fluoro, and lodo . For some purposes within the scope of this invention, chloro, bromo and fluoro are especially preferred halogens.
  • Compounds of Formula III are particularly useful for the preparation of cryophycin compounds.
  • the starting material corresponding to a compound of Formula 1 as illustrated in Scheme 1 can be prepared using the disclosures available to the skilled artisan. See Barrow, id.
  • the processes for preparing compound 2 as illustrated in Scheme 1' used TFA; however, the artisan will recognize that alternative agents can be used in this process.
  • the basic workup uses sodium hydroxide; however, the artisan will appreciate that other basic agents can be effective as well.
  • the processes to prepare the compounds of this invention most preferably are completed m the presence of a solvent.
  • a solvent selected from the group consisting of toluene, N,N-d ⁇ methylformamide, ethyl acetate, tetrahydrofuan, and acetonitrile.
  • the reaction time is related to the starting materials and operating temperature. The optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.
  • the catalyst is most preferrably selected from the group consisting of alky and aryl substituted metal carboxylates, carboxylic acids, and other bifunctional compounds according to the Formula IV.
  • Especially preferred catalysts are selected from the group consisting of 2-hydroxy ⁇ yridine, tetrabutylammonium cyanide and sodium benzoate/n-tetrabutylNHS0 4 .
  • the filtered solution of amino ester 2 was diluted to 500 mL and 2-hydroxypyridine (5.34, 56.2 mmoles) was added. The resulting clear, pale yellow solution was allowed to stir at room temperature for 14 h. The reaction mixture became turbid so the suspension was diluted with CH2CI2 (250 mL) to assure solubility of product. The mixture was washed with saturated, aqueous NaHC0 3 (3 x 100 mL) and brine (1 x 100 L) . The aqueous extracts were back-extracted with CH 2 CI 2 (1 x 100 mL) and the organic extracts were combined, dried (MgS0 4 ) , and concentrated to a thick syrup.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention provides novel cryptophycin compounds and a process for preparing cryptophycin compounds.

Description

PROCESS TO PREPARE PHARMACEUTICAL COMPOUNDS
This invention relates to the fields of pharmaceutical and organic chemistry and provides a process for preparing cryptophycin compounds useful as anti- microtubule agents.
Cryptophycin compounds can be useful for the treatment of cancer and neoplasms, and are thus useful pharmaceutical agents. The literature discloses a protocol for cyclizing certain cryptophycin compounds. Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S . ; Moore, R. E.; Tius, M. A. J. Am. Chem . Soc . 1995, 11 7, 2479. This three-step sequence (hereinafter "Barrow synthetic sequence") commenced with the conversion of trichloroethyl ester to the corresponding carboxylic acid using zinc and acetic acid. Conversion of crude to the amino carboxylate was accomplished with trifluoroacetic acid followed by an aqueous basic work-up. In the final step, ring closure was achieved in the presence of pentafluorophenyldiphenylphosphinate (FDPP) in N,N- dimethylformamide to provide the desired product 3 (3 is illustrated infra , in Scheme 1 to provide further clarification) (61% after chromatography) .
In contrast, the presently claimed process provides a shorter (two-steps) process which is more adaptable for large scale or commercial preparation of the macrocyclic core of cryptophycin derivatives. The claimed process can reduce reagent expense, as well as minimize the potential waste-stream issues associated with the use of certain reagents in the Barrow synthetic sequence. Further, purification via the claimed process may be accomplished without chromatography, which is expensive and difficult to implement on a large scale.
The presently claimed invention provides a process for preparing a compound of Formula II
Figure imgf000004_0001
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, d-Ci? alkyl, C?-Cι2 alkenyl, C6-C1? alkynyl, NR51R52, COR5 , OR5', and Formula Ar'
Figure imgf000004_0002
R >5311 is selected from the group consisting of hydrogen and C- C3 alkyl;
R5 is selected from the group consisting of hydrogen and d~ C3 alkyl;
R53 is selected from the group consisting of Cι~Cι2 alkyl; R54 is selected from the group consisting of hydrogen, d~C6 alkyl, Ci-dalkyl (R5 'R57"R57'" ) , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( tert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR57, P03H, S03H, S02R, N(R59)R60,
Figure imgf000004_0003
NHCHR61', CN, NO?, halogen, OR62, CH2(0)R6", -
R"
CH?OC(0)R , CH2N(R 9y6e \)R>9y6b' , COR ,100 (d-dalkyl)OR 100 and
SR 63 , R95 is selected from the group consisting of -R98NH3; R9b and R96' are each independently selected from the group consisting of hydrogen and d-C6 alkyl, -R97NH3, and -R99 NR99' R99"; R97 is selected from the group consisting of Cι-Cfe alkyl; R98 is selected from the group consisting of d-Ce alkyl; R99 is d-C6 alkyl;
R99' and R9C" ' are each independently selected from the group consisting of hydrogen and Cι-C6 alkyl; R100 is selected from the group consisting of hydrogen, and s i ( R1 0 , R1 02R103 ) .
R101 is Cι -C6 alkyl ;
R: o? i s d-Ce, alkyl ;
R103 is C -C6 al kyl ; R104 is selected from the group consisting of C ( 0) d -C6 alkylN (R10fa) (R59) R60, C ( 0) d-C6 alkylN+ , fused bicyclic, and
NHR105N (R106) (R59) R60;
R105 is selected from the group consisting of C(0,d-C6 alkyl,
Cι-C6 alkyl; R106 is selected from the group consisting of hydrogen, -d alkyl, C(0)OR107;
R107 is selected from the group consisting of hydrogen, d_d alkyl, CR108 R109 Rno
R108 is selected from the group consisting of hydrogen and Cι-C6 alkyl;
R109 is selected from the group consisting of hydrogen and
Cι-C6 alkyl;
R110 is selected from the group consisting of hydrogen and d-C6 alkyl; R55 is selected from the group consisting of hydrogen, Cι-C6 alkyl, C (R57'R57"R57'" ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR57, P03H, S03H, S02R58,
NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63; R5b i s selected from the group consisting of hydrogen, Cι -Cb al kyl , C ( R 7 ' R57 " R57" ' ) , simple unsubstituted aromat ic, simple substituted aromatic , phenyl , COORf57 , P03H, S03H, S02R58 ,
NR59Rb0, NHORbl , NHCHR61' , (d-C6) alkylNR59R6 , CN, N02, halogen, OR104 , CR104 , OR62 , and SR63 ;
R^ is selected from the group cons i sting o f hydrogen and d -
C12 al kyl ;
R57' is selected from the group consisting of hydrogen, halogen, and C1-C12 alkyl; R57" is selected from the group consisting of hydrogen, halogen, and C~Cι2 alkyl;
R57'" is selected from the group consisting of hydrogen, halogen, and d-C12 alkyl;
R58 is selected from the group consisting of hydrogen and Cj- C1? alkyl;
R59 is selected from the group consisting of hydrogen, (Cι~
Cfc) alkyl, tert-butoxycarbonyl, carbo-tert-butoxy (t-BOC) and fluorenylmethoxycarbonyl (FMOC) ;
R60 is selected from the group consisting of hydrogen and (Ci-d) alkyl;
R61 is selected from the group consisting of hydrogen, OR1'4,
CH2NHR65, NHR65' and fluorenylmethoxycarbonyl (FMOC);
R61' is selected from the group consisting of hydrogen, OR64,
CH2NHR65, NHR6 and fluorenylmethoxycarbonyl (FMOC) ; R6? is selected from hydrogen, and d-Cb alkyl;
R62' is selected from hydrogen, OH, OR62, and d~Cb alkyl;
Rbi is selected from hydrogen and Cj-d, alkyl;
R64 is selected from the group consisting of hydrogen, (Ci-
C6) alkyl, CH2NR66R67; RG5 is selected from the group consisting of hydrogen and Ci-
C6 alkyl, NH2, and fluorenylmethoxycarbonyl (FMOC) ;
R65' is selected from the group consisting of hydrogen and
Cι-Cfa alkyl, NH2, and fluorenylmethoxycarbonyl (FMOC) ; R66 is selected from the group consisting of hydrogen and Ci- d alkyl and fluorenylmethoxycarbonyl (FMOC) ;
R6' is selected from the group consisting of hydrogen and Ci-
C6 alkyl; R3 is a lower alkyl group;
R4 is H or OH;
R5 is H or OH;
R4 and R5 may be taken together to form a second bond between 3 and d R6 is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring (d-C6) alkyl, (d-C8) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (C,-Cb) alkyl, a group of the formula III'
Figure imgf000007_0001
and a group of the formula III ' '
Figure imgf000007_0002
R7 is selected from the group consisting of NR R',?, R53NR R5?, OR53, H and a lower alkyl group; R51 and R"'2 are independently selected from the group consisting of d_d alkyl; R53 is d~ C3 alkyl; R8 is H or a lower alkyl group; or R7 and R8 can form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-C3-d cycloalkyl, and benzyl; R10 is H or a lower alkyl group;
Rn is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl;
Rιr', Rl , and R1 ' are each independently selected from the group consisting of hydrogen, OR18, halo, NR18'R19', N02,
OP03H2, OR19phenyl, SCH2phenyl, CONH , C0?H,
Figure imgf000008_0001
and
ZZ;
R18 is selected from the group consisting of hydrogen, aryl,
Cι-Cb alkyl, C(0)R90 and fluorenylmethoxycarbonyl (FMOC); R18' is selected from the group consisting of hydrogen, (d-
C6) alkyl and C(0)R90' ;
R19 is Ci- alkyl, C(0)R9n" and fluorenylmethoxycarbonyl
( FMOC) ;
R19' is selected from the group consisting of hydrogen, (d~ C alkyl, and C (0) R90'" ;
R90, R90' , R90" , and R90" ' are each independently selected from the group consisting of hydrogen, (Ci-d) alkyl, OR91' and aryl;
R91' is selected from the group consisting of (Ci-d) alkyl, aryl, and hydrogen;
R23 is selected from the group consisting of hydrogen and
(d-d) alkyl;
R30 is hydrogen or Ci- alkyl; or
R may be taken together with the N at C-11 to form a three to seven me bered cyclic ring;
R50 is hydrogen or
Figure imgf000008_0002
n is 0, 1, or 2; m is 0, 1, or 2; -1-
p is 0, l,or 2;
X is selected from the group consisting of 0, C, S, NH and alkylamino;
Y is selected from the group consisting of C, O, NH, S, SO,
S02 and alkylamino;
Z is selected fromt he group consisting of -(CH2)n-, -(CH?)P-
0-(CH?)m- and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; comprising contacting a compound of Formula III
Figure imgf000009_0001
with a solvent and a catalyst of the formula IV
vcat
Figure imgf000009_0002
wherein M is selected from the group consisting of hydrogen, Na, Li, K, and Cs;
Xcat is selected from the group consisting of 0, N, and S; ycat _s selected from the group consisting of 0, N, and S;
Rcatl is selected from the group consisting of Cι~ C6 alkyl and aryl; Rcat2 is selected from the group consisting of Cι~
Ce alkyl and aryl.
Additionally, the present invention provides a new cryptophycin compound of Formula III
Figure imgf000010_0001
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, C] -Cι2 al kyl , C2-CJ 2 alkenyl, C2-C12 alkynyl, NRbllrR-,52 CORs OR 53 and Formula Ar'
Figure imgf000010_0002
R51 is selected from the group consisting of hydrogen and Ci- C3 alkyl;
R 52 is selected from the group consisting of hydrogen and d~
C3 alkyl;
R 53 is selected from the group consisting of Cι-Cι2 alkyl;
R is selected from the group consisting of hydrogen, Ci- alkyl, d~dalkyl (R5 'Rb7"R57'" ) , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( tert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR57, PO^H, S03H, S07R, N(R59)R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, CH2(0)Rε?'
Figure imgf000011_0001
Figure imgf000011_0002
CH2N(R96)R9b',COR100, (d-C6alkyl) OR100, , and
SR63,
R is selected from the group consisting of -R NH3; R96 and R96' are each independently selected from the group consisting of hydrogen and Ci- alkyl, -R9NH3, and -R9 NR99'
R99";
R97 is selected from the group consisting of Cι-Ch alkyl;
R98 is selected from the group consisting of C]-Cf, alkyl; R99 is Ci-Ce alkyl;
R99' and R99" are each independently selected from the group consisting of hydrogen and d_ alkyl;
R100 is selected from the group consisting of hydrogen, and
Si (R101R102R103) ; R101 is d-Ce alkyl;
R102 is d-d alkyl;
R103 is d-d alkyl;
R104 is selected from the group consisting of C(0)Cι-Cb alkylN(R106) (R59)RB0, C (0) C,-C6 alkylN+, fused bicyclic, and NHR105N(R106) (Rf,9)R60;
R105 is selected from the group consisting of C(0)d-C6 alkyl,
Cι-Cβ alkyl;
R106 is selected from the group consisting of hydrogen, Cι~C6 alkyl, C(0)OR107; R107 is selected from the group consisting of hydrogen, Cι~C alkyl, CR108 R109 R110
R108 is selected from the group consisting of hydrogen and
Ci-d alkyl;
R109 is selected from the group consisting of hydrogen and d-d alkyl;
R o is selected from the group consisting of hydrogen and
Ci-d alkyl; R111 is selected from the group consisting of hydrogen, d-Cb alkyl, and C(0)0R107
R55 is selected from the group consisting of hydrogen, d~d alkyl, C (R57'R57"R5'"' ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR57, P03H, S03H, S02R58,
NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63;
R56 is selected from the group consisting of hydrogen, Cι~d alkyl, C (R 7'R '"Rh7'" ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR57, P0H, S03H, S0?R58, NRb9R60, NHOR61, NHCHR61', (C,-C6) alkylNRb9RG0, CN, NO,, halogen,
OR104, CR104, OR62, and SR63;
R57 is selected from the group consisting of hydrogen and d- d? alkyl;
R57' is selected from the group consisting of hydrogen, halogen, and d-C12 alkyl;
R57" is selected from the group consisting of hydrogen, halogen, and Cι-C12 alkyl;
R57'" is selected from the group consisting of hydrogen, halogen, and Cι-Cι2 alkyl; R58 is selected from the group consisting of hydrogen and d-
C12 alkyl;
R59 is selected from the group consisting of hydrogen, (Ci-
C6) alkyl, tert-butoxycarbonyl, carbo-tert-butoxy (t-BOC) and fluorenylmethoxycarbonyl (FMOC) ; R60 is selected from the group consisting of hydrogen and (d-d) alkyl;
R61 is selected from the group consisting of hydrogen, OR ,
CH2NHRes, NHR65' and fluorenylmethoxycarbonyl (FMOC);
R61' is selected from the group consisting of hydrogen, OR64, CH2NHR65, NHR65' and fluorenylmethoxycarbonyl (FMOC) ;
R62 is selected from hydrogen, and C_ alkyl;
R62' is selected from hydrogen, OH, OR62, and Ci-d alkyl;
R63 is selected from hydrogen and Ci- alkyl; Rb4 is selected from the group consisting of hydrogen, (Ci-
C6) alkyl, CH2NR66R67;
R65 is selected from the group consisting of hydrogen and d-
C6 alkyl, NH2, and fluorenylmethoxycarbonyl (FMOC) ; R65' is selected from the group consisting of hydrogen and
Cι-C6 alkyl, NH2, and fluorenylmethoxycarbonyl (FMOC) ;
R66 is selected from the group consisting of hydrogen and d-
C6 alkyl and fluorenylmethoxycarbonyl (FMOC) ;
R67 is selected from the group consisting of hydrogen and d- Cb alkyl;
RJ is a lower alkyl group;
R4 is H or OH;
R' is H or OH;
R4 and R5 may be taken together to form a second bond between C13 and d4;
R6 is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring
(Ci-Ce) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (Ci-d) alkyl, a group of the formula III'
Figure imgf000013_0001
and a group of the formula III''
Figure imgf000014_0001
R7 is selected from the group consisting of NR51R5?, R53NR51R51,
OR53, H and a lower alkyl group; R51 and R52 are independently selected from the group consisting of C1-C3 alkyl; R53 is Ci- C3 alkyl;
R8 is H or a lower alkyl group; or
R7 and Re can form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-C3-Cb cycloalkyl, and benzyl;
R10 is H or a lower alkyl group;
R11 is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl; Rlb, R16, and R17 are each independently selected from the group consisting of hydrogen, OR18, halo, NR18'R19', N02,
OP03H2, OR19phenyl, SCH henyl, CONH2, C0H, P03H2, S02R23, and
ZZ;
R18 is selected from the group consisting of hydrogen, aryl, d-C6 alkyl, C(0)R90 and fluorenylmethoxycarbonyl (FMOC);
R18' is selected from the group consisting of hydrogen, (Ci-
C6) alkyl and C(0)R90';
R19 is d-Ce alkyl, C(0)R90" and fluorenylmethoxycarbonyl ( MOC) ; R:9' is selected from the group consisting of hydrogen, (Ci-
C6) alkyl, and C(0)R90"';
R90, R90' , R90" , and R90'" are each independently selected from the group consisting of hydrogen, (Ci-Ce) alkyl, OR91' and aryl; R91' is selected from the group consisting of (Cι-d) alkyl, aryl, and hydrogen;
R2J is selected from the group consisting of hydrogen and
(d-d) alkyl; R30 is hydrogen or Cι~C6 alkyl; or
R30 may be taken together with the N at C-11 to form a three to seven membered cyclic ring; o
R50 is hydrogen or ; n is 0 , 1 , or 2 ; m is 0 , 1 , or 2 ; p is 0 , l , or 2 ;
X is selected from the group consisting of 0, C, S, NH and alkylamino; Y is selected from the group consisting of C, 0, NH, S, SO, S02 and alkylamino;
Z is selected fromt he group consisting of -(CH2)n-, - (CH?) P- 0-(CH2)m- and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof.
As used herein, the term "simple alkyl" shall refer to C2.-C7 alkyl wherein the alkyl may be saturated, unsaturated, branched, or straight chain. Examples include, but are in no way limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, propenyl, ethenyl, sec-butyl, n-pentyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, methylated pentyl groups and the like. The term "alkenyl" refers to an alkyl group, as defined above, having from one to three double bonds. The term "alkynyl" refers to an alkyl group, as defined above, having at least one triple bond. It is especially preferred that alkynyl has only one triple bond. The term Ci-Cn> alkyl; wherein n' is an integer from 1 to 12 means an alkyl group having from one to the indicated number of carbon atoms. The Ci-Cn1 alkyl can be straight or branched chain. As used herein, the term "B-ring Ci-Cβ alkyl" refers to saturated, unsaturated, branched and straight chain alkyl wherein the B-ring Ci-Cβ alkyl group may include up to three (3) non-carbon substituents. Such non-carbon substituents are most preferredly selected from the group) consisting of OH, SCH phenyl, NH2, CO, CONH2, C02H, P03H2,
S02R21 wherein R21 is selected from hydrogen and C3.-C3 alkyl;
As used herein, the term " (Ci-Cβ) alkyl linker" refers to Ci-Cβ alkyl group having from zero to three substituents selected from the group consisting of Cχ-C6 alkyl, NH2 and amino acid.
As used herein the term "amino acid" means an organic acid containing an amino group. The term includes both naturally occuring and synthetic amino acids, therefore, the amino group can be, but is not required to be, attached to the carbon next to the acid. The term shall refer to, but is in no way limited to (CH ) 2NH2COOH, (CH2) 3NH2COOC(CH3) 3, CH2NH2COOC (CH3) 3, CH2CH (NH2 ) CH2COOH, CH2CH(NH2)CH2COOC(CH3)3, and the like.
As used herein, the term "carbohydrate" refers to a class of substituents made up of carbon, hydrogen, and oxygen wherein hydrogen and oxygen are in the same proportions as in water or nearly the proportions as water. The term "carbohydrate" further refers to an aldehyde or ketone alcohol or a compound which on hydrolysis produces and aldehyde or ketone. The term "carbohydrate" is as commonly understood by the skilled artisan. For example,, the term refers to, but is in no way limited to, Cι2H 20n and C6H10O5. As used herein, the term "amino sugar" refers to a carbohydrate group containing from one to three amino substituents at any available position on the carbohydrate molecule . As used herein, the term "saccharide" refers to carbohydrate subunits to form disaccharides or polysaccharides . The term means for example, but in no way limited to, lactose, maltose, sucrose, fructose, starch, and the like. As used herein, the term "substituted phenyl" shall refer to a phenyl group with from one to three non- hydrocarbon substituents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I. As used herein, the term "substituted benzyl" shall refer to a benzyl group with from one to three non- hydrocarbon substitutents which may be independently selected from the group consisting of simple alkyl, Cl, Br, F, and I wherein such substituents may be attached at any available carbon atom. As used herein "B-ring heterocyclic group" refers to aromatic or unsaturated rings which contain one or more non-carbon substituent selected from the group consisting of oxygen, nitrogen, and sulfur. Especially preferred B-ring heterocyclic groups are selected from, but not limited to, the group consisting of
20
Figure imgf000018_0001
R20 is selec ed from hydroge alkyl. wherein R20 is selected from hydrogen and Ci-Cβ alkyl.
It is especially preferred that "B-ring heteroaromatic group" refers to a substituent selected from the group consisting of:
Figure imgf000018_0002
As used herein "cycloalkyl" refers to a saturated C-C cycloalkyl group wherein such group may include from zero to three substituents selected from the group consisting of C1-C3 alkyl, halo, and OR22 wherein R22 is selected from hydrogen and C1-C3 alkyl. Such substituents may be attached at any available carbon atom. It is especially preferred that cycloalkyl refers to substituted or unsubstituted cyclohexyl.
As used herein "Lower alkoxyl group" means any alkyl group of one to five carbon atoms bonded to an oxygen atom. As used herein "lower alkyl group" means an alkyl group of one to five carbons and includes linear and non- linear hydrocarbon chains, including for example, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, methylated butyl groups, pentyl, tert pentyl, sec-pentyl, and methylated pentyl groups. As used herein "allylically substituted alkene" means any alkene having from one to seven carbon atoms which contains an alkyl substitution on it. As used herein the term "unsaturated lower alkyl" means a lower alkyl group as defined supra , wherein from one to two double bonds are present in the unsaturated lower alkyl substituent. A preferred unsaturated lower alkyl is -CH2-CH=CH . The term "lower alkyl-C3~C5 cycloalkyl" refers to C-C alkyl substituted with a C3-C5cycloalkyl group. A preferred lower alkyl-C3~C5 cycloalkyl group is -CH2-cyclopropyl; wherein the group is attached to the cryptophycin core structure at R9 via the CH2.
As used herein "epoxide ring" means a three- membered ring whose backbone consists of two carbons and an oxygen atom. As used herein, "aziridine ring" means a three-me bered ring whose backbone consists of two carbon atoms and a nitrogen atom. As used herein "sulfide ring" means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom. As used herein "episulfide ring" means a three-membered ring whose backbone consists of two carbon atoms and a sulfur atom. As used herein "sulfate group" means a five membered ring consisting of a carbon- carbon-oxygen-sulfur-oxygen backbone with two additional oxygen atoms connected to the sulfur atom. As used herein "cyclopropyl ring" means a three member ring whose backbone consists of three carbon atoms. As used herein, "monoalkylphosphate ring" means a five membered ring consisting of a carbon-carbon-oxygen-phosphorous-oxygen backbone with two additional oxygen atoms, one of which bears a lower alkyl group, connected to the phosphorous atom.
As used herein, "simple unsubstituted group" refers to common aromatic rings having 4n+2 π electrons in a monocyclic conjugated system, for example, but not limited to: furyl, pyrrolyl, thienyl, pyridyl and the like, or a bicyclic conjugated system, for example but not limited to mdolyl or naphthyl. As used herein "simple substituted aromatic group" refers to a phenyl group substituted with a single group selected from the group consisting of halogen and lower alkyl group.
As used herein, the term "fused bicyclic" refers to two joined ring systems which are optionally independently saturated, unsaturated, or aromatic. Such groups include but are in no way limited to naphthyl, groups which fuse an unsaturated ring with an aromatic ring, groups having a heterocyclic group fused with a heteroaromatic group, and a heterocyclic group fused with an aromatic group. The fused bicyclic is optionally substituted with one or more substituents selected from the group consisting of Ci- alkyl and halogen.
As used herein, "heteroaromatic group" refers to aromatic rings which contain one or more non-carbon atoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. It is most preferred that the heteroaromatic group will have from three to eight members in the ring. It is especially preferred that the number of non-carbon members will be from one to three.
As used herein, the term "heterocyclic" refers to saturated or unsaturated rings containing one or more non carbon atoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. It is most preferred that the heterocyclic group will have from three to eight members m the ring. It is especially preferred that the number of non-carbon members will be from one to three.
As used herein, "halogen" or "halo" refers to those members of the group on the periodic table historically known as halogens. Methods of halogenation include, but are not limited to, the addition of hydrogen halides, substitution at high temperature, photohalogenation, etc., and such methods are known to the skilled artisan. Especially preferred halogens are chloro, bromo, fluoro, and lodo . For some purposes within the scope of this invention, chloro, bromo and fluoro are especially preferred halogens.
Compounds of Formula III are particularly useful for the preparation of cryophycin compounds.
The starting material corresponding to a compound of Formula 1 as illustrated in Scheme 1 can be prepared using the disclosures available to the skilled artisan. See Barrow, id. The processes for preparing compound 2 as illustrated in Scheme 1' used TFA; however, the artisan will recognize that alternative agents can be used in this process. Likewise, the basic workup uses sodium hydroxide; however, the artisan will appreciate that other basic agents can be effective as well.
The processes to prepare the compounds of this invention most preferably are completed m the presence of a solvent. The skilled artisan can select appropriate solvents using known methodologies. While in no way limiting the scope of the present invention, some preferred solvents are provided for the guidance of the artisan, including, but not limited to, a solvent selected from the group consisting of toluene, N,N-dιmethylformamide, ethyl acetate, tetrahydrofuan, and acetonitrile. The reaction time is related to the starting materials and operating temperature. The optimum reaction time for a given process is, as always, a compromise which is determined by considering the competing goals of throughput, which is favored by short reaction times, and maximum yield, which is favored by long reaction times.
The process of this invention can be further illustrated by the following Scheme 1' :
Figure imgf000022_0001
And more particularly, Scheme 1:
Figure imgf000022_0002
catalyst ►
Toluene, rt
Figure imgf000022_0003
As illustrated above, the catalyst is most preferrably selected from the group consisting of alky and aryl substituted metal carboxylates, carboxylic acids, and other bifunctional compounds according to the Formula IV. Especially preferred catalysts are selected from the group consisting of 2-hydroxyρyridine, tetrabutylammonium cyanide and sodium benzoate/n-tetrabutylNHS04.
The following is provided to further illustrate the advantages of the claimed process:
As shown in Table 1, 2-hydroxypyridine (entries 2-4) and tetrabutylammonium benzoate (entry 5) have been shown to significantly accelerate the macrolactamization process. In contrast, ring closure was very slow when the reaction was allowed to stir at room temperature without catalyst (entry 1) . Although not listed in Table 1, tetrabutylammonium cyanide (NaBu4NCN + NaCN) also promoted macrolactamization of 2. As shown in Table 1, the 2 and 3 refer to the structures of Scheme 1 wherein Ar is phenyl. TABLE 1
Figure imgf000023_0001
Example 1 Cryptophycin-51 (3) .
Compound 1 (as illustrated by Scheme 1 supra . ) (10.2 g,
11.2 ol) was cooled to 0 °C and dissolved in trifluoroacetic acid (TFA) (50 mL) . The resulting solution was stirred at 0 °C for 30 min and was then concentrated under reduced pressure. The resultant syrup was diluted with toluene (250 L) and washed with IN NaOH (2x100 mL) using brine (50 mL) to break up emulsions. The aqueous extracts were back-extracted with fresh toluene (1x50 L) and the organic phases were combined and dried (MgS04) . TLC analysis indicated no trace of starting 1. The filtered solution of amino ester 2 was diluted to 500 mL and 2-hydroxypyridine (5.34, 56.2 mmoles) was added. The resulting clear, pale yellow solution was allowed to stir at room temperature for 14 h. The reaction mixture became turbid so the suspension was diluted with CH2CI2 (250 mL) to assure solubility of product. The mixture was washed with saturated, aqueous NaHC03 (3 x 100 mL) and brine (1 x 100 L) . The aqueous extracts were back-extracted with CH2CI2 (1 x 100 mL) and the organic extracts were combined, dried (MgS04 ) , and concentrated to a thick syrup. A solution of hexanes and EtOAc (100 mL, 1:1 v/v) was added and the solution was cooled to 0 °C. Spontaneous crystallization occurred after 30 min. The mixture was filtered, and the filtrate was concentrated and induced to crystallize two additional times. The collected crops were combined to give 5.04 g (69%) of compound 3 (LSN 354504) as a white powder. HPLC (85:15 CH3CN / H20, 0.05% TFA in both organic and aqueous phases; flow 1 mL / min; wavelength: 225 nm; column: Zorbax SB-C18) Rt = 6.09 min 95% pure. XH NMR (300 MHz, CDCI3) d 7.32-7.17 (m, 8H) ; 7.04 (dd, 1H, J= 2.2, 8.4); 6.82 (d, 1H, J = 8.5); 6.76 (m, 1H) ; 6.39 (d, 1H, J= 15.9); 5.99 (dd, 1H, J = 8.8, 15.8); 5.73 (dd, 1H, J = 2.3, 16.4); 5.50 (d, 1H, J = 7.8); 5.03 (m, 1H) ; 4.83 (dd, 1H, J = 3.3, 9.9); 4.73 (ABq, 1H, J= 6.4); 3.86 (s, 3H) ; 3.39 (dd, 1H, J= 8.6, 13.5); 3.10 (m, 2H) ; 2.53 (m, 2H) ; 2.36 (m, 1H) ; 1.62 (m, 3H) ; 1.21 (s, 3H) ; 1.14 (s, 3H) ; 1.11 (d, 3H, J = 6.9) ; 0.71 (app. t, 6H, J = 6.0) .

Claims

We claim:
A compound of Formula III
Figure imgf000026_0001
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, -Cι alkyl, d-Cι2 alkenyl, C2-C1? alkynyl, NR!,'R:;, COR'2, OR'", and Formula Ar-'
Figure imgf000026_0002
Rbl is selected from the group consisting of hydrogen and C--
C, alkyl;
R2 is selected from the group consisting of hydrogen and d-
C3 alkyl;
S3 is selected from the group consisting of Ci-Ci: alkyl;
54 is selected from the group consisting of hydrogen, C.--C. alkyl, d-dalkyl (RΓ,7'R5 "R"" ' ) , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( tert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR", P0.,H, SdH, S0?R,
N(Rjy)Rb , NH0R ,6b1 , NHCHR ,6b1l , CN, N02, halogen, OR , CH2(0)Rc: ' CHrOC(0)R CH?N(R'b)Ryt , COR1nr (d-C.-.alkyl)OR, 1 Of
Figure imgf000027_0001
and
R95 is selected from the group consisting of -R98NH,;
R9b and R96' are each independently selected from the group consisting of hydrogen and Ci-d. alkyl, -R NH,, and -R NR
R99";
R9/ is selected from the group consisting of Ci-d alkyl;
R98 is selected from the group consisting of C-,-d, alkyl;
R99 is Ci-d alkyl;
R9 ' and R9"" are each independently selected from the group consisting of hydrogen and Cι~d- alkyl;
R10ϋ is selected from the group consisting of hydrogen, and si (R:o-!Rio2Rim) ;
101 is d-d alkyl
10? is Ci-d alkyl
103 is Ci- alkyl
R 104 is selected from the group consisting of C(0)d-C, alkylN(Rluc) (Rj9)Rb , C(0)d-d alkylN+, fused bicyclic, and
NHR10!,N(R10") (R5 )R60, Rlor' is selected from the group consisting of C(0)C-C alkyl, Ci-d alkyl;
R 106 is selected from the group consisting of hydrogen, C-.-C, alkyl, C(0)0R 107 ,
R1 is selected from the group consisting of hydrogen, C--C. alkyl, CR ,1108 R ,110') R .n' o
R ,1J0U8D is selected from the group consisting of hydrogen and Ci-d; alkyl;
R 109 is selected from the group consisting of hydrogen and d-d alkyl;
Rno is selected from the group consisting of hydrogen and
Ci-d alkyl; R: is selected from the group consisting of hydrogen, Ci-C, alkyl, and C(0)OR107
R55 is selected from the group consisting of hydrogen, Ci-C, alkyl, C (Rr'''R57"R57" ' ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR'7, P03H, SO^H, S0-R3 ,
NR:,9Rb0, NHOR61, NHCHR61', CN, NO,, halogen, OR'" , and SRC'\-
*R b is selected from the group consisting of hydrogen, C.-C. alkyl, C (R5''R5 "R57' " ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl,
Figure imgf000028_0001
PO.H, SO,H, SO Rri, NR59R60, NHOR61, NHCHR61', (d -C6) alkylNR^R' , CN, N0 , halogen,
OR10", CR '\ OR62, and SR°;
Rh' is selected from the group consisting of hydrogen and C -
Ci: alkyl;
R57' is selected from the group consisting of hydrogen, halogen, and C]-Cι2 alkyl;
R^" is selected from the group consisting of hydrogen, halogen, and d -Cι2 alkyl ;
R57'" is selected from the group consisting of hydrogen, halogen, and d -C12 alkyl ; R~>a is selected from the group cons i st ing o f hydrogen and C -
Ci ; alkyl ;
R59 is selected from the group consisting of hydrogen, (C,-
Cb) alkyl, tert-butoxycarbonyl, carbo-tert-butoxy (t-BOC) and fluorenylmethoxycarbonyl (FMOC); R is selected from the group consisting of hydrogen and (d-d) alkyl;
R61 is selected from the group consisting of hydrogen, ORυ" ,
CH2NHR6\ NHR6 and fluorenylmethoxycarbonyl (FMOC);
R61' is selected from the group consisting of hydrogen, ORb" ,
Figure imgf000028_0002
NHR65' and fluorenylmethoxycarbonyl (FMOC);
R62 is selected from hydrogen, and Ci-d alkyl;
R62' is selected from hydrogen, OH, OR"', and d-d, alkyl;
R63 is selected from hydrogen and d.-C, alkyl; Rb is selected from the group consisting of hydrogen, (d- d ) alkyl , CH2NR6bR67 ;
R65' is selected from the group consisting of hydrogen and d
Co alkyl, NH2, and fluorenylmethoxycarbonyl (FMOC) ;
R 65' is selected from the group consisting of hydrogen and
Ci-Cβ alkyl, NH2, and fluorenylmethoxycarbonyl
R 66 is selected from the group consisting of hydrogen and C
C6 alkyl and fluorenylmethoxycarbonyl (FMOC) ;
R6' is selected from the group consisting of hydrogen and d- d alkyl;
R3 is a lower alkyl group; R is H or OH; R5 is H or OH;
R4 and R5 may be taken together to form a second bond between C]3 and C14;
R is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring
(Ci-Cfi) alkyl, (d-d) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (Ci- ) alkyl, a group of the formula III'
Figure imgf000029_0001
and a group of the formula III1':
Figure imgf000029_0002
III R' is selected from the group consisting of NR51R2, RjNRM3. ,
OR'^, H and a lower alkyl group; RM and R' ' arc independently selected from the group consisting of Ci-d alkyl; R"'1 is C -
C3 alkyl; RB is H or a lower alkyl group; or
R' and R8 can form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-d-d, cycloalkyl, and benzyl; Rj0 is H or a lower alkyl group;
R11 is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl;
R15, Rlb, and R17 are each independently selected from the group consisting of hydrogen, OR1", halo, NR18'R1Q', N02,
OP03H2, 0R19phenyl, SCH.phenyl, CONH,, C02H, PO.H. , S02R \ and
ZZ;
R1B is selected from the group consisting of hydrogen, aryl, d-d alkyl, C(0)R90 and fluorenylmethoxycarbonyl (FMOC); R18' is selected from the group consisting of hydrogen, (C - d) alkyl and C (O)R90' ;
R19 is Cι~ alkyl, C(0)R9"" and fluorenylmethoxycarbonyl ( FMOC) ;
R19' is selected from the group consisting of hydrogen, (C-- CG) alkyl, and C (0) R90'" ;
Rq°, R90' , R90" , and R90'" are each independently selected from the group consisting of hydrogen, (Ci-C,,) alkyl, OR91' and aryl;
R91' is selected from the group consisting of (C]-Cb) alkyl , aryl, and hydrogen;
R23 is selected from the group consisting of hydrogen and (C,-d) alkyl;
R30 is hydrogen or Cι~Cfi alkyl; or R30 may be taken together with the N at C-11 to form a three to seven membered cyclic ring;
R50 is hydrogen or
Figure imgf000031_0001
n is 0, 1, or 2;
Figure imgf000031_0002
p is 0, 1 , or 2;
X is selected from the group consisting of O, C, S, NH and alkylamino;
Y is selected from the group consisting of C, 0, NH, S, SO,
SO; and alkylamino;
Z is selected fromt he group consisting of -(CH,),,-, -(CH, ) -
0-(CH2),r- and (d-d) cycloalkyl;
ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound of Claim 1 wherein the compound of
Formula III is defined as follows:
Figure imgf000031_0003
wherein
Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C1-C12 alkyl, C1-C12 alkene, C1-C12 alkyne, NR51R52, OR53, Formula Ar '
Figure imgf000032_0001
R51 is selected from the group consisting of hydrogen and
C1-C3 alkyl;
R52 is selected from the group consisting of hydrogen and C1-C3 alkyl;
R53 is selected from the group consisting of C1-C12 alkyl
R54 is selected from the group consisting of hydrogen, C|-C alkyl, simple aromatic, phenyl, COOR57, PO3H, SO3H, S02R ,
NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63; R55 is selected from the group consisting of hydrogen, Cχ-C0 alkyl, simple aromatic, phenyl, COOR57, PO3H, SO3H, S02R58,
NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63;
R56 is selected from the group consisting of hydrogen, Ci-Cβ alkyl, simple aromatic, phenyl, COOR57, PO3H, SO3H, S02R5 , NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR6^, and SR ;
R57 is selected from the group consisting of hydrogen and
C1-C12 alkyl;
R58 is selected from the group consisting of hydrogen and
C1-C12 alkyl; R59 is selected from the group consisting of hydrogen, (Cj.-
Cς, ) alkyl and fluorenylmethoxycaronyl (FMOC);
R60 is selected from the group consisting of hydrogen and (Cι-C6) alkyl;
R61 is selected from the group consisting of hydrogen, OR64, CH2NHR65, NHR65 and fluorenylmethoxycaronyl (FMOC);
R61' is selected from the group consisting of hydrogen, OR64, CH2NHR65, NHR65 and fluorenylmethoxycaronyl (FMOC) ; R62 is selected from hydrogen and Cχ-C6 alkyl; R63 is selected form hydrogen and Ci-Cβ alkyl; R64 is selected from the group consisting of hydrogen, (C|- C6) alkyl, CH2NR66R67 R65 is selected from the group consisting of hydrogen and
Ci-Cδ alkyl, NH2, and fluorenylmethoxycaronyl (FMOC) ;
R66 is selected from the group consisting of hydrogen and
Ci-Ce alkyl and fluorenylmethoxycaronyl (FMOC);
R67 is selected from the group consisting of hydrogen and
Cι-C6 alkyl;
R3 is a lower alkyl group;
R4 is H or OH;
Figure imgf000033_0001
R4 and R5 may be taken together to form a second bond between C13 and C14;
R6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl , or dihaloalkoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B- ring (Ci-Cβ) alkyl, (C3-C8) cycloalkyl, substituted C3-C8 cycloalkyl, substituted (Ci-Cβ) alkyl, a group of the formula III' :
' and a group of the formula III
Figure imgf000033_0002
",
R7 is H or a lower alkyl group;
R8 is H or a lower alkyl group;
R9 is H or a lower alkyl group;
R10 is H or a lower alkyl group;
R11 is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl; R15, R16, and R17 are each independently selected from the group consisting of hydrogen, (C1-C6) lkyl , OR18, halo, NR18'R19', N02, OPO4H2, OR19phenyl, SCH2phenyl, CONH2, C02H, PO3H2, S02R23, and ZZ; R18 is selected from the group consisting of hydrogen, aryl, and C1-C6 alkyl; R18' is selected from the group consisting of hydrogen and
(Ci-Ce) alkyl; R19 is Ci-Cβ alkyl; R19' is selected from the group consisting of hydrogen and
(Ci-Ce) alkyl; R23 is selected from the group consisting of hydrogen and
(C1-C3) alkyl; R30 is hydrogen or Ci-Cβ alkyl;
R50 is hydrogen or
Figure imgf000034_0001
; n is 0, 1 , or 2
Figure imgf000034_0002
m is 0, 1 , or 2
Figure imgf000034_0003
X is 0, NH or alkylamino;
Y is C, 0, NH, S, SO, S02 or alkylamino;
Z is selected from the group consisting of -(CH2)n~/
- (CH2)p-0- (CH2)m- and (C3-C5) cycloalkyl ;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group; or a pharmaceutically acceptable salt thereof.
3. A compound of Claim 1 wherein Ar is selected from the group consisting of phenyl, aromatic, or simple substituted aromatic.
4. A compound of Claim 2 wherein Ar is a parafluoro substituted phenyl ring.
5. A compound of Claim 1 wherein R > is hydrogen,
R7 and R8 are each methyl, X is 0, Y is 0, and Rϋ is a group
of the formula Λ
6. A compound of Claim 1 wherein R Hi is hydrogen, one of R7 and R8 is methyl, X is 0, Y is 0, and Rrf is a.
group of the formuil.a
Figure imgf000035_0001
7. A process for preparing a compound of Formula II
Figure imgf000035_0002
wherein
Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, substituted heteroaromatic group, unsubstituted heteroaromatic group, heterocyclic, d-d_ alkyl, C_-C . alkenyl, C2-Cι2 alkynyl, NR51Rr' , COR^, 0R'\ and Formula Ar'
Figure imgf000035_0003
R is selected from the group consisting of hydrogen and C - d alkyl;
Rj2 is selected from the group consisting of hydrogen and C - d alkyl;
R53 is selected from the group consisting of Cι-Cι? alkyl;
R54 is selected from the group consisting of hydrogen, C -C alkyl, d-C6alkyl (R57'R57"R57'") , simple unsubstituted aromatic, simple substituted aromatic, heterocyclic, phenyl, halogen, 4- ( ert-butyldimethylsiloxy) - benzyltriphenylphosophonium, COOR' , POjH, S03H, SO-R , N(R ))R 0, NHOR61, NHCHR61', CN, NO.., halogen, OR6', CHr(0)R62'
R1'
Figure imgf000036_0001
CH?OC CH2N(R9b)R9b' ,CORlϋn, (d-d alkyl ) OR10", , and
SR62; R9'J is selected from the group consisting of -R'"NH ;
R9b and R96' are each independently selected from the group consisting of hydrogen and Ci-d alkyl, -R9'NH(, and -R99 NR9"'
R9'" ' ;
R97 is selected from the group consisting of Ci-d alkyl; R9B is selected from the group consisting of Ci-d alkyl;
R99 is Ci-C,. alkyl;
R99' and R9<1" are each independently selected from the group consisting of hydrogen and Ci-d alkyl;
R100 is selected from the group consisting of hydrogen, ard Si(RιnιR10R103);
R101 is Ci-d alkyl;
Rlo: is Ci-d, alkyl;
R103 is Ci-d alkyl;
R104 is selected from the group consisting of C(0)C.-C, alkylN(Rκ"') (R', )Rf°, C(0)Cι-C„ alkylNf, fused bicyclic, and
NHR105N(R106) (R'j9)R (l;
R10'' is selected from the group consisting of C(0)d-d alkyl, d-d alkyl;
R106 is selected from the group consisting of hydrogen, C,-C alkyl, C(0)0R107;
R10' is selected from the group consisting of hydrogen, Ci-C. alkyl, CR108 R109 R110
R108 is selected from the group consisting of hydrogen and
Cι-Cb alkyl; Rloq is selected from the group consisting of hydrogen and
Ci-d alkyl; R110 is selected from the group consisting of hydrogen and
Ci- alkyl;
R"5 is selected from the group consisting of hydrogen, C-,-C, alkyl, C (R 7'R57"R-'7' " ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR57, P03H, SO,H, S02Ri,β,
NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SRυ";
R is selected from the group consisting of hydrogen, Ci-C, alkyl, C ( R^' R51 " R^'1 " ' ) , simple unsubstituted aromatic, simple substituted aromatic, phenyl, COOR5'1, PdH, S03H, S02R5H, NRiR6°, NHOR61, NHCHR61', (d-C6) alkylNR59R60, CN, N02, halogen,
OR104, CR10\ OR62, and SR63;
R57 is selected from the group consisting of hydrogen and C--
C12 alkyl;
R57' is selected from the group consisting of hydrogen, halogen, and C1-C12 alkyl;
R5'" is selected from the group consisting of hydrogen, halogen, and Cι-CT2 alkyl;
R^'" is selected from the group consisting of hydrogen, halogen, and Cι-Cι2 alkyl; R58 is selected from the group consisting of hydrogen and C--
Ci; alkyl;
R*13 is selected from the group consisting of hydrogen, (d-
C6) alkyl, tert-butoxycarbonyl, carbo-tert-butoxy (t-BOC) and fluorenylmethoxycarbonyl (FMOC); RoC is selected from the group consisting of hydrogen and
(d-d) alkyl;
R61 is selected from the group consisting of hydrogen, OR64,
Figure imgf000037_0001
NHR6 and fluorenylmethoxycarbonyl (FMOC);
R61' is selected from the group consisting of hydrogen, OR6'1,
Figure imgf000037_0002
NHR65' and fluorenylmethoxycarbonyl (FMOC);
R62 is selected from hydrogen, and Cι-Cc alkyl;
R62' is selected from hydrogen, OH, ORb2, and Ci-C,-, alkyl;
R63 is selected from hydrogen and C:-C,; alkyl; R64 is selected from the group consisting of hydrogen, (Ci d) alkyl, CH?NRb6R6
Rb is selected from the group consisting of hydrogen and C - d alkyl, NH?, and fluorenylmethoxycarbonyl (FMOC);
R6 is selected from the group consisting of hydrogen and
Cι-C6 alkyl, NH , and fluorenylmethoxycarbonyl (FMOC);
R6<r is selected from the group consisting of hydrogen and C - d alkyl and fluorenylmethoxycarbonyl (FMOC);
R67 is selected from the group consisting of hydrogen and C - d alkyl;
R * I S a lower alkyl group ;
R4 is H or OH;
Figure imgf000038_0001
R4 and R5 may be taken together to form a second bond between d< and d„;
Rb is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl , halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring
(Ci-d) alkyl, (d-Cn) cycloalkyl , substituted d-CH cycloalkyl, substituted (Cι~Cb) alkyl, a group of the formula III'
Figure imgf000038_0002
and a group of the formula III''
Figure imgf000038_0003
III R' is selected from the group consisting of NRslRrι2, R,J,NR51R' ,
OR", H and a lower alkyl group; RM and R^*' are independently selected from the group consisting of - alkyl; R" is C--
C3 alkyl; R° is H or a lower alkyl group; or
R' and R8 can form a cyclopropyl ring;
R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-d-d cycloalkyl, and benzyl; R10 is H or a lower alkyl group;
R11 is selected from the group consisting of hydrogen, OH, lower alkyl group, substituted phenyl, benzyl, substituted benzyl and phenyl;
R15, R"6, and R17 are each independently selected from the group consisting of hydrogen, OR18, halo, NRlh"R1< , N02,
OP03H2, OR1?phenyl, SCH2phenyl, CONH., CO.-H, P03H2,
Figure imgf000039_0001
and
ZZ;
R is selected from the group consisting of hydrogen, aryl,
Ci-d alkyl, C(0)R90 and fluorenylmethoxycarbonyl (FMOC); R18' is selected from the group consisting of hydrogen, (C,-
Cc) alkyl and C(0)R90';
R19 is Ci-d alkyl, C(0)R9n" and fluorenylmethoxycarbonyl
( FMOC) ;
R19' is selected from the group consisting of hydrogen, (d- C6) alkyl, and C(0)R90"';
R90, R90' , R90" , and R90' " are each independently selected from the group consisting of hydrogen, (d-d,) alkyl , OR9'' and aryl;
R91' is selected from the group consisting of (Ci-C alkyl, aryl, and hydrogen;
R23 is selected from the group consisting of hydrogen and
(d-d) alkyl;
R30 is hydrogen or Cι~C6 alkyl ; or R30 may be taken together with the N at C-11 to form a three to seven membered cyclic ring;
R50 is hydrogen or
Figure imgf000040_0001
n is 0, 1, or 2; m is O, 1, or 2 ; p is 0, 1 , or 2;
X is selected from the group consisting of O, C, S, NH and alkylamino;
Y is selected from the group consisting of C, 0, NH, S, SO, S02 and alkylamino;
Z is selected fromt he group consisting of -(CH2),,-, -(CH ):- 0-(CH )n- and (d-d,) cycloalkyl;
ZZ is selected from the group consisting of a simple unsubstituted aromatic group and a simple substituted aromatic group; comprising contacting a compound of Formula III
Figure imgf000040_0002
with a solvent and a catalyst of the formula IV
Figure imgf000041_0001
ιy wherein M is selected from the group consisting of hydrogen, Na, Li, K, and Cs;
Xcat is selected from the group consisting of O, N, and S; ycat _s selected from the group consisting of 0, N, and S;
Rcatl _s selected from the group consisting of Cj.- C Q alkyl and aryl;
Rcat2 is selected from the group consisting of Cι~ C6 alkyl and aryl.
8. A process of Claim 7 wherein the solvent is selected from the group consisting of toluene, N,N- dimethylformamide, ethyl acetate, tertrahydrofuran and acetonitrile .
9. A process of Claim 7 wherein the Formula II compound is defined as follows
Figure imgf000041_0002
wherein
Ar is phenyl or any simple unsubstituted or substituted aromatic or heteroaromatic group, C]_-Cι alkyl, C1-C12 alkene, C1-C12 alkyne, NR51R52, OR53, Formula Ar '
Figure imgf000042_0001
R51 is selected from the group consisting of hydrogen and
C1-C3 alkyl;
R52 is selected from the group consisting of hydrogen and
C1-C3 alkyl;
R53 is selected from the group consisting of C1-C12 alkyl;
R54 is selected from the group consisting of hydrogen, d-Co alkyl, simple aromatic, phenyl, COOR57, PO3H, SO3H, S02R5e ,
NR59 R 60 / NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63;
R55 is selected from the group consisting of hydrogen, Cj.-Cc alkyl, simple aromatic, phenyl, COOR57, P03H, SO3H, S02Rb ,
NR59 R 60 / NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR63;
R56 is selected from the group consisting of hydrogen, C1-C0 alkyl, simple aromatic, phenyl, COOR57, PO3H, SO3H, S02R5 , NR59R60, NHOR61, NHCHR61', CN, N02, halogen, OR62, and SR;
R57 is selected from the group consisting of hydrogen anc.
C1-C12 alkyl;
R58 is selected from the group consisting of hydrogen and
C1-C12 alkyl; R59 is selected from the group consisting of hydrogen, (C'ι-
Cβ) alkyl and fluorenylmethoxycaronyl (FMOC);
R60 is selected from the group consisting of hydrogen and (Cι-C6) alkyl;
R61 is selected from the group consisting of hydrogen, OR64, CH2NHR65, NHR65 and fluorenylmethoxycarony i (FMOC);
R61' is selected from the group consisting of hydrogen, OR64, CH2NHR65, NHR65 and fluorenylmethoxycaronyl (FMOC); R62 is selected from hydrogen and Ci-Cδ alkyl; R63 is selected form hydrogen and Ci-Ce alkyl;
R64 is selected from the group consisting of hydrogen, C6) alkyl, CH2NR66R67 R65 is selected from the group consisting of hydrogen and
Ci-Cβ alkyl, NH2, and fluorenylmethoxycaronyl (FMOC);
R66 is selected from the group consisting of hydrogen and
Cι~C6 alkyl and fluorenylmethoxycaronyl (FMOC);
R67 is selected from the group consisting of hydrogen and
C1-C6 alkyl;
R3 is a lower alkyl group;
R4 is H or OH;
R5 is H or OH;
R4 and R5 may be taken together to form a second bond between C 3 and Cι ;
R6 is selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, fi¬ ring (Ci-Cδ) alkyl, (C3-C8) cycloalkyl , substituted C3-C8 cycloalkyl, substituted (Ci-Cδ) alkyl, a group of the formula III* :
' and a group of the formula III
Figure imgf000043_0001
",
R7 is H or a lower alkyl group;
R8 is H or a lower alkyl group;
R9 is H or a lower alkyl group;
R10 is H or a lower alkyl group;
R11 is selected from the group consisting of H, OH, simple alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl; R15, R16, and R17 are each independently selected from the group consisting of hydrogen, (Ci-Cβ) alkyl , OR18, halo, NR18'R19', N02, OP0 H2, 0R19phenyl, SCH2phenyl, CONH2, C02H, P03H2, S02R23, and ZZ; R18 is selected from the group consisting of hydrogen, aryi, and Ci-Cβ alkyl; R18' is selected from the group consisting of hydrogen and
(Ci-Ce) alkyl; R19 is Cι-C6 alkyl; R19' is selected from the group consisting of hydrogen and
(Cι-C6) alkyl;
R23 is selected from the group consisting of hydrogen and
(C1-C3) alkyl; R30 is hydrogen or Ci-Cβ alkyl;
R50 is hydrogen or
Figure imgf000044_0001
; n is 0, 1, or 2; p is 0, 1, or 2;
Figure imgf000044_0002
q is 2, 3, or 4; X is O, NH or alkylamino;
Y is C, 0, NH, S, SO, S02 or alkylamino;
Z is selected from the group consisting of -(CH2)n~>
- (CH2)p-0- (CH2)m- and (C3-C5) cycloalkyl;
ZZ is selected from the group consisting of an aromatic group and a substituted aromatic group.
10. A process of Claim 7 wherein the solvent is toluene .
11. A process of Claim 7 wherein Ar is aromatic or substituted aromatic.
12. A process of Claim 7 wherein R3' is hydrogen,
R7 and Rb are each methyl, X is 0, Y is 0, and Rc ' is a group
of the formula Λ
13. A process of Claim 7 wherein R is hydrogen, one of R' and R8 is methyl, X is 0, Y is 0, and Rn is a
group of the formula A
PCT/US1997/015668 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds WO1998009601A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU43343/97A AU4334397A (en) 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds
EP97941436A EP0934250A4 (en) 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds
IL12864397A IL128643A0 (en) 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds
CA002264527A CA2264527A1 (en) 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds
JP10512938A JP2001500128A (en) 1996-09-06 1997-09-05 Method for producing a medicinal composition
BR9711695-5A BR9711695A (en) 1996-09-06 1997-09-05 Process for preparing pharmaceutical compounds
IL128643A IL128643A (en) 1996-09-06 1999-02-21 Process for preparing cryptophycin compounds and some new intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2543796P 1996-09-06 1996-09-06
US60/025,437 1996-09-06

Publications (2)

Publication Number Publication Date
WO1998009601A2 true WO1998009601A2 (en) 1998-03-12
WO1998009601A3 WO1998009601A3 (en) 1998-04-23

Family

ID=21826065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015668 WO1998009601A2 (en) 1996-09-06 1997-09-05 Process to prepare pharmaceutical compounds

Country Status (9)

Country Link
EP (1) EP0934250A4 (en)
JP (1) JP2001500128A (en)
KR (1) KR20010029475A (en)
AU (1) AU4334397A (en)
BR (1) BR9711695A (en)
CA (1) CA2264527A1 (en)
HU (1) HUP0000212A3 (en)
IL (2) IL128643A0 (en)
WO (1) WO1998009601A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911088A1 (en) * 1999-03-12 2000-09-28 Fraunhofer Ges Forschung Assembly device for manually assembling mechanical, electromechanical and/or optical components has device for operating mounting tool as well as operation element for moving assembly head
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039829A1 (en) * 1995-06-07 1996-12-19 University Of Hawaii New cryptophycins
WO1996040184A1 (en) * 1995-03-07 1996-12-19 University Of Hawaii New cryptophycins from synthesis
WO1997007798A1 (en) * 1995-08-30 1997-03-06 Eli Lilly And Company Pharmaceutical compounds
WO1997023211A1 (en) * 1995-12-22 1997-07-03 Eli Lilly And Company Pharmaceutical compounds
EP0792875A1 (en) * 1996-02-27 1997-09-03 Eli Lilly And Company Cryptophycin derivatives and their use as anti-microtubule agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427706T2 (en) * 1993-12-21 2001-10-25 Univ Hawaii Honolulu CRYPTOPHYCINE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040184A1 (en) * 1995-03-07 1996-12-19 University Of Hawaii New cryptophycins from synthesis
WO1996039829A1 (en) * 1995-06-07 1996-12-19 University Of Hawaii New cryptophycins
WO1997007798A1 (en) * 1995-08-30 1997-03-06 Eli Lilly And Company Pharmaceutical compounds
WO1997008334A1 (en) * 1995-08-30 1997-03-06 University Of Hawaii Cryptophycins from aberrant biosynthesis
WO1997023211A1 (en) * 1995-12-22 1997-07-03 Eli Lilly And Company Pharmaceutical compounds
EP0792875A1 (en) * 1996-02-27 1997-09-03 Eli Lilly And Company Cryptophycin derivatives and their use as anti-microtubule agents

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS ON STN, No. 1997:113412, MOORE RICHARD E., "Isolation, Characterization and Synthesis of New Cryptophycin Compounds as Anticancer Agents"; & WO,A,96 40184, (19 December 1996). *
DATABASE CAPLUS ON STN, No. 1997:140250, MOORE et al., "New Cryptophycins for Inhibition of Cell Proliferation"; & WO,A,96 39829, (19 December 1996). *
DATABASE CAPLUS ON STN, No. 1997:244384, MOORE et al., "Cryptophycin Derivatives for Disrupting the Microtubule System"; & WO,A,97 07798, (06 March 1997). *
DATABASE CAPLUS ON STN, No. 1997:257479, MOORE et al., "Cryptophycins from Aberrant Biosynthesis"; & WO,A,97 08334, (06 March 1997). *
DATABASE CAPLUS ON STN, No. 1997:503417, SHIU CHUAN, "Preparation of Novel Cryptophycin Compounds as Anti-Microtubule Agents"; & WO,A,97 23211, (03 July 1997). *
DATABASE CAPLUS ON STN, No. 1997:604154, NORMAN B.H. et al., "Preparation of New Cryptophycin Derivatives and Their Use as Anti-Microtubule Agents"; & EP,A,792 875, (03 August 1997). *
J. AM. CHEM. SOC., 08 March 1995, Vol. 117, No. 9, BARROW et al., "Total Synthesis of Cryptophycins. Revision of the Structures of Cryptohycins A and C", pages 2479-2490. *
J. ORG. CHEM., 06 September 1996, Vol. 61, No. 18, REJ et al., "Total Synthesis of Cryptophycins and their 16-(3-Phenylacryloyl) Derivatives", pages 6289-6295. *
See also references of EP0934250A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911088A1 (en) * 1999-03-12 2000-09-28 Fraunhofer Ges Forschung Assembly device for manually assembling mechanical, electromechanical and/or optical components has device for operating mounting tool as well as operation element for moving assembly head
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
EP2289549A2 (en) 1999-10-01 2011-03-02 Immunogen, Inc. Immunoconjugates for treating cancer

Also Published As

Publication number Publication date
IL128643A0 (en) 2000-01-31
EP0934250A2 (en) 1999-08-11
HUP0000212A3 (en) 2001-12-28
EP0934250A4 (en) 2004-08-11
IL128643A (en) 2006-04-10
JP2001500128A (en) 2001-01-09
WO1998009601A3 (en) 1998-04-23
AU4334397A (en) 1998-03-26
BR9711695A (en) 2000-03-08
HUP0000212A2 (en) 2000-07-28
KR20010029475A (en) 2001-04-06
CA2264527A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
Steliou et al. Reagents for organic synthesis. Part 3. Tin-mediated esterification in macrolide synthesis
US5807847A (en) Nitrate esters
Melby et al. Improved Synthesis of tetrathiafulvalene
Naya et al. The photosensitized oxygenation of furanoeremophilanes. II. The preparation and stereochemistry of the isomeric hydroperoxides and the corresponding lactones from furanofukinin and furanoeremophilane.
AU775482B2 (en) A process for obtaining (nitroxymethyl)phenyl esters of salicylic acid derivatives
WO1998009601A2 (en) Process to prepare pharmaceutical compounds
Herscheid et al. Biosynthesis of gliotoxin. Synthesis of sulfur-bridged dioxopiperazines from N-hydroxyamino acids
NZ537993A (en) Process for preparing nitrooxyderivatives of naproxen
US4501919A (en) Process for the production of serine derivatives
Czekanski et al. Synthesis and electrochemical properties of benzo [b] naphtho [2, 3-e][1, 4]-dioxin-6, 11-quinones and their N, N'-dicyano quinone diimine derivatives
Watanabe The Chemical Structure of the Intermediate Metabolites of Catechin I–IV: Chemical Properties of the Intermediate Metabolites (G and H) and their Derivatives Oxidative Decomposition of the Intermediate Metabolites (G and H) Synthesis of the Intermediate Metabolites (G and H) Structure of the Intermediate Metabolite (F)
Attaby Reactions with cyanothioacetamide derivatives: Synthesis of several new pyridine and annelated pyridine derivatives
Gataullin The first synthesis of benzo [e] cycloalk [g] oxazocinone atropisomers via lactonization of N-mesyl-or N-arylsulfonyl-N-[2-(1-cycloalken-1-yl)-6-methylphenyl] glycines
Van der Huizen et al. The reactivity of the cyclic systems (NPCl2) 3− n (NSOX) n (n= 0, 1; X= Cl, Ph) towards aziridine
ANTHONI et al. IV. Dimerization of/V-Isothioeyanatodimethylamine
Kondo et al. S. fwdarw. N and N. fwdarw. S reverse rearrangement of S-and N-(2, 4-dinitrophenyl) cysteines
Heinrich et al. Effective syntheses of quinoline-7, 8-diol, 5-amino-l-DOPA, and 3-(7, 8-dihydroxyquinolin-5-yl)-l-alanine
JPH0140033B2 (en)
Watanabe et al. Cycloaddition and Oxidation Reactions of a Stable Thioaldehyde,(2, 4, 6-Tri-t-butyl) thiobenzaldehyde.
Liao et al. Synthesis of spiroimidazolidin-2-ones via intramolecular N-carbamoyliminium ion cyclization reactions
EP0157444B1 (en) 3-azinomethyl rifamycins
NOGUCHI et al. Convenient One-pot Syntheses of Sulfinates, Sulfinamides, and Thiosulfinates by Sulfinylation with p-Toluenesulfinic Acid and Activating Reagents
SU461510A3 (en) Method for preparing alkylsulfonic acid esters of 1,3,2-oxazaphosphacyclic compounds
CH622808A5 (en)
Aizina et al. N-(2, 2, 2-trichloroethylidene)-and N-(1-hydroxy-2, 2, 2-trichloroethyl) amides in C-amidoalkylation reaction of functionally-substituted aromatic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09029185

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264527

Country of ref document: CA

Ref country code: CA

Ref document number: 2264527

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997941436

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002150

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 512938

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019997001858

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997941436

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997001858

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019997001858

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997941436

Country of ref document: EP